HLN
Haleon plcHealthcare · $39.7B market cap
Verdict
Share price
$8.80
close of Oct 3, 2026
Fair value
$5.71
Sticker Price
Payback Price
$2.28
buy price
HLN is Overpriced: at $8.80 it trades 54% above its fair value of $5.71. Its buy price (Payback Price) is $2.28, 74% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 1% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow HLN
Get notified when it reaches its buy price of $2.28. Free.
Create a free accountSuperinvestors
5 of the investors we track hold HLN. In Q2 2026, 1 added. Who we track
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$1.4B
149,934,507 shares
Bill Nygren
Oakmark Funds · as of Q2 2026
$157.1M
16,833,252 shares
First Eagle Investment Management
First Eagle Investment Management · as of Q2 2026
$39.4M
4,224,856 shares
Tweedy Browne
Tweedy Browne · as of Q2 2026
$672K
72,035 shares
Kahn Brothers Group
Kahn Brothers Group · as of Q2 2026
$565K
56,431 shares
Moves in Q2 2026
Added: Bill Nygren
About Haleon plc
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works